STARPHARMA APPOINTS HEAD CHEMIST

Melbourne (Australia) 6 August 2002: Starpharma Pooled Development Limited (ASX: SPL) today announced that Dr Guy Krippner has joined the company as Head Chemist Dr Krippner has more than 10 years post-doctoral experience in synthetic organic and medicinal chemistry. He has developed, and worked extensively in, medicinal chemistry programs with two other Australian biotechnology companies, designing and preparing new drug compounds. Dr Krippner has been part of commercially focused project teams developing drugs targeting viral respiratory diseases and Alzheimer's Disease.

Starpharma CEO, Dr John Raff, said, "The appointment of Dr Krippner further strengthens Starpharma's experienced synthetic chemistry team. Dr Krippner's commercial experience in drug discovery and development programs will make a valuable contribution to the Starpharma as we develop and commercialise dendrimer nanodrugs."

Starpharma Limited, a wholly owned subsidiary of Starpharma Pooled Development Limited (SPL), is a biopharmaceutical company focussed on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma Limited has an extensive intellectual property portfolio relating to dendrimer nanotechnology.

CONTACTS:

Dr John Raff

Chief Executive Officer +61 3 8532 2701

Mr Ben Rogers Company Secretary +61 3 8532 2702

www.starpharma.com